Adverse reactions of immune checkpoint inhibitors combined with Proton pump inhibitors: a pharmacovigilance analysis of drug-drug interactions
Based on real-world data, four Standardized MedDRA Query System Organ Class toxicities were identified as drug-drug interactions associated with combining immune checkpoint and proton pump inhibitors. Clinicians should be cautious when administering these drugs concomitantly. Preclinical trials and robust clinical studies are required to explore the mechanisms and relationships underlying interactions, thus improving understanding of drug-drug interactions associated with this combination therapy.
Authors
- Li Lu (ORCID: https://orcid.org/0000-0003-0977-6414)
- Xiayang Ren (ORCID: https://orcid.org/0000-0003-3279-5082)
- Xiangli Cui (ORCID: https://orcid.org/0000-0002-2992-5205)
- Rui Wan (ORCID: https://orcid.org/0000-0002-7177-7736)
- Yanfeng Wang (ORCID: https://orcid.org/0000-0002-3196-2347)
- Yiran Chen (ORCID: https://orcid.org/0000-0002-9507-4007)
Institutions
- Capital Medical University (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- National Cancer Center (US)
- Beijing Friendship Hospital (CN)
Publication Details
- Journal
- BMC Cancer
- Published
- 2024-09-27
- DOI
- https://doi.org/10.1186/s12885-024-12947-7
- Citations
- 6
- Primary Topic
- Pharmacovigilance and Adverse Drug Reactions
- Type
- article
- Field-Weighted Citation Impact
- 2.10
Funders
- Peking Union Medical College
- Cancer Foundation of China
- Bijzonder Onderzoeksfonds UGent